--- title: "Avadel Sets Court Date for Alkermes Acquisition Scheme" type: "News" locale: "en" url: "https://longbridge.com/en/news/273077517.md" description: "Avadel Pharmaceuticals has announced that the High Court of Ireland will hold a sanction hearing on February 10, 2026, regarding Alkermes plc's acquisition of all issued and to-be-issued ordinary shares of Avadel. The takeover offer commenced on October 22, 2025, and is expected to close soon after court approval. Analysts rate AVDL stock as a Buy with a $25.00 price target, while TipRanks’ AI Analyst gives it a Neutral score due to improving operational trends but ongoing profitability challenges." datetime: "2026-01-20T11:37:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273077517.md) - [en](https://longbridge.com/en/news/273077517.md) - [zh-HK](https://longbridge.com/zh-HK/news/273077517.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273077517.md) | [繁體中文](https://longbridge.com/zh-HK/news/273077517.md) # Avadel Sets Court Date for Alkermes Acquisition Scheme ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The latest update is out from Avadel Pharmaceuticals ( (AVDL) ). On January 19, 2026, Avadel Pharmaceuticals announced that the High Court of Ireland has scheduled a sanction hearing for February 10, 2026 to consider a scheme of arrangement under which Alkermes plc will acquire all issued and to-be-issued ordinary shares of Avadel. The offer period for this takeover began on October 22, 2025, and the transaction is expected to close shortly after the court sanctions the scheme, with the company outlining Irish Takeover Rules disclosure obligations for shareholders holding or dealing in 1% or more of Avadel’s relevant securities, underscoring the formal progression and regulatory framework of the pending acquisition. The most recent analyst rating on (AVDL) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page. **Spark’s Take on AVDL Stock** According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral. The score is driven primarily by improving operational trends (revenue growth and strong cash-flow improvement) and a stable balance sheet with minimal leverage, but held back by continued lack of profitability (negative net margin and ROE). Technicals are moderately positive, while valuation is weak due to losses and a negative P/E. Corporate events provide meaningful upside support via the approved acquisition and other favorable developments. To see Spark’s full report on AVDL stock, click here. **More about Avadel Pharmaceuticals** **Average Trading Volume:** 3,099,558 **Technical Sentiment Signal:** Buy **Current Market Cap:** $2.1B For an in-depth examination of AVDL stock, go to TipRanks’ Overview page. ### Related Stocks - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [Alkermes plc (ALKS.US)](https://longbridge.com/en/quote/ALKS.US.md) - [Avadel Pharmaceuticals plc (AVDL.US)](https://longbridge.com/en/quote/AVDL.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [Alkem Laboratories Gets Board Nod to Boost Investment in New Factory](https://longbridge.com/en/news/281495465.md) - [TD Cowen Sticks to Their Buy Rating for Alkermes (ALKS)](https://longbridge.com/en/news/281419637.md) - [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md) - [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md) - [Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC](https://longbridge.com/en/news/281174396.md)